Fleury (FLRY3.SA) Aktie Kurs

Fleury SA is primarily active in the healthcare industry.

The main competitors of Fleury SA in the market include Grupo Fleury, DASA, and Hermes Pardini.

Fleury SA is a leading healthcare company based in Brazil. With a rich history dating back to 1926, Fleury has continually evolved and expanded its operations to become one of the most reputable diagnostic medicine providers in the country. Over the years, the company has developed a strong reputation for its advanced diagnostic techniques and high-quality services, encompassing radiology, pathology, and clinical analysis. With a strong focus on technological innovation, Fleury has consistently invested in cutting-edge equipment and research, enabling them to deliver accurate and reliable results to patients. Today, Fleury SA stands as a trusted name in the healthcare industry, providing comprehensive diagnostic solutions to improve patient outcomes.

Fleury SA, a renowned company, has achieved remarkable milestones throughout its history. Having established a strong presence in the healthcare sector, Fleury SA continuously strives for excellence. Some significant achievements include expanding its network and becoming one of the largest healthcare providers in Brazil. Additionally, Fleury SA has consistently prioritized innovation, implementing advanced technology and processes to deliver high-quality diagnostics and medical solutions. The company's commitment to patient-centric care and a strong focus on research & development have further solidified its position as a trusted leader in the industry. Fleury SA's relentless pursuit of growth and unwavering dedication to improving healthcare services have contributed to its notable achievements.

Fleury SA is primarily present in Brazil, where it operates a wide network of diagnostic medicine and healthcare facilities. With its headquarters in São Paulo, the company is a leader in medical laboratory services, operating in several states across the country. Fleury SA's commitment to providing high-quality diagnostic services has allowed it to expand its presence to other regions of Brazil, catering to a diverse range of patients and medical professionals.

Fleury SA represents a strong set of values and corporate philosophy. With a focus on excellence and innovation, the company strives to deliver the highest quality healthcare services to patients. Fleury SA is committed to providing accurate diagnoses, personalized care, and cutting-edge medical technology. Through continuous improvement, the company aims to surpass industry standards and meet the evolving needs of its customers. With a reputation for professionalism and integrity, Fleury SA upholds a patient-centric approach, putting the well-being and satisfaction of individuals at the forefront. By encompassing these values, Fleury SA remains a trusted leader in the healthcare industry.

Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 17,77 BRL for Fleury-aktien (median: 18,36 BRL), svarende til -16,4 % i forhold til seneste kurs. Konsensus bygger på 19 analytikervurderinger.

Fleury Analytikerens Kursmål 2026

18 analytikere vurderer i øjeblikket Fleury-aktien: 11 anbefaler køb, 5 hold og 2 salg. For 2026 forventer analytikere, at Fleury genererer omsætning på 9,28 Mrd. BRL og indtjening pr. aktie på 1,47 BRL.

Fleury Analytikerens Kursmål 2026

Omregnet til den aktuelle valutakurs handles Fleury-aktien til 3,42 EUR (21,26 BRL).

Fleury-aktien (FLRY3.SA) er noteret på 2 børser, herunder: B3 (São Paulo) (FLRY3.SA).

Fleury SA is a company specializing in medical diagnostics and health services. Founded in 1926, the company is headquartered in Sao Paulo, Brazil. With over 9,000 employees and a revenue of more than 2.2 billion Brazilian Reals, Fleury SA is one of the largest medical service companies in South America. The business model of Fleury SA is based on three core areas: diagnostics, health services, and research and development. In diagnostics, the company enables disease identification and offers comprehensive diagnostic solutions. The portfolio of diagnostic services is very broad and includes imaging and radiological diagnostics, laboratory and pathology services, genetic testing, and screening for pregnancy-related diseases. In the field of health services, Fleury SA offers a wide range of services for individuals and companies looking to improve prevention, wellness, and quality of life. The services range from health counseling and health programs to outpatient surgery and rehabilitation facilities. In research and development, the company is interested in driving innovation in the fields of medical diagnostics and health services. Fleury SA invests heavily in the development of new technologies and solutions to improve the accuracy and efficiency of its diagnostic services, as well as in collaboration with academic institutions and other companies. The company is known for adhering to very high quality standards in all aspects of its services. Fleury SA is ISO 9001 certified and is committed to continuously working towards customer satisfaction and process optimization. The company is proud to offer state-of-the-art technology and top-notch medical professionals to provide customers with the best possible service. In addition to its business areas, Fleury SA also offers a variety of products, such as diagnostic instruments and consumables for medical professionals, medical software, and health products for the general public. The products are designed to meet the needs of medical professionals and private consumers and meet the highest quality standards. Overall, Fleury SA has an impressive track record in the field of medical diagnostics and health services. The company has established itself as a trusted provider of high-quality and innovative solutions over the past decades and is committed to continuing to lead the industry with excellence and groundbreaking innovations.

forventet-omsætningen for Fleury er 9,28 Mrd. BRL. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for Fleury er 802,35 Mio. BRL. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Fleury er i øjeblikket 14,44. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Fleury-aktien.

Pris-til-salgs-forholdet (P/S) for Fleury er i øjeblikket 1,25. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Fleury-aktien.

AlleAktien-kvalitetsscore for Fleury er 8/10.

ISIN for Fleury er BRFLRYACNOR5. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

Tickeren for Fleury er FLRY3.SA. Tickersymbolet bruges til at handle Fleury-aktier på børsen.